Neurosarcoidosis
42 Neurosarcoidosis Brandon P. Moss and Jinny Tavee KEY POINTS FOR THE CLINICIAN • Neurologic complications are seen in 5% to 10% of patients with systemic sarcoidosis, but are the presenting…
Neuromyelitis Optica
PART VI. RELATED DISEASES 38 Neuromyelitis Optica Amanda L. Piquet and John R. Corboy KEY POINTS FOR THE CLINICIAN • Neuromyelitis optica (NMO) is a distinct clinical–pathological disease that is…
Treating Relapsing Forms of Multiple Sclerosis: Infusion Therapies
14 Treating Relapsing Forms of Multiple Sclerosis: Infusion Therapies Jenny J. Feng and Daniel Ontaneda KEY POINTS FOR CLINICIANS • There are six infusion therapies for the treatment of relapsing forms…
Cognitive Dysfunction in Multiple Sclerosis
21 Cognitive Dysfunction in Multiple Sclerosis Stephen M. Rao KEY POINTS FOR CLINICIANS Cognitive dysfunction … • Occurs in 43% to 65% of patients with multiple sclerosis (MS) • Is often under…
Emerging Therapies
16 Emerging Therapies Michael D. Kornberg and Peter A. Calabresi KEY POINTS FOR CLINICIANS • Current disease-modifying therapies target the peripheral immune system with a primary goal of preventing relapses. • The…
Pediatric Multiple Sclerosis
PART V. SPECIAL ISSUES 33 Pediatric Multiple Sclerosis Amy T. Waldman KEY POINTS FOR CLINICIANS • Pediatric and adult multiple sclerosis (MS) have similar clinical symptoms. • The presence of encephalopathy…
Overview of Rehabilitation in Multiple Sclerosis
PART IV. REHABILITATION AND SYMPTOM MANAGEMENT 17 Overview of Rehabilitation in Multiple Sclerosis Francois Bethoux KEY POINTS FOR CLINICIANS • Rehabilitation refers to a variety of interventions that aim…
Treating Relapsing Forms of Multiple Sclerosis: Injection and Oral Therapies
13 Treating Relapsing Forms of Multiple Sclerosis: Injection and Oral Therapies Le H. Hua KEY POINTS FOR CLINICIANS • There are currently 15 approved disease-modifying therapies for multiple sclerosis (MS). • The…
American Academy of Neurology Guidelines for Multiple Sclerosis Disease-Modifying Therapy
PART III. TREATMENT 2018 American Academy of Neurology Guidelines for Multiple Sclerosis Disease-Modifying Therapy Alexander D. Rae-Grant In April 2018, the American Academy of Neurology (AAN) published a systematic…
Epidemiology and Natural History of Multiple Sclerosis
224 Epidemiology and Natural History of Multiple Sclerosis Marcus W. Koch KEY POINTS FOR CLINICIANS • The incidence and prevalence of multiple sclerosis (MS) varies between different geographical regions and ethnicities….
